What Is Tirzepatide?
Last reviewed:
Tirzepatide (research code LY3298176) is a synthetic 39-amino-acid lipidated peptide engineered from the GIP sequence and classified as a dual GIP / GLP-1 receptor agonist. It is one of the most extensively characterised incretin research molecules. Tirzepatide is also the active ingredient of registered prescription medicines; the material described here is a laboratory reference standard, not a medicine.
How is Tirzepatide classified and what is its structure?
Tirzepatide is a 39-amino-acid synthetic peptide built on the glucose-dependent insulinotropic polypeptide (GIP) backbone, incorporating non-natural amino acids (Aib) and a C20 fatty-diacid chain attached via a linker at lysine 20. The lipidation supports albumin binding, which is why it is described in the literature as a long-acting analogue.
Its research code is LY3298176. It is chemically distinct from single-receptor GLP-1 agonists such as semaglutide.
How is Tirzepatide’s mechanism studied in research?
Published pharmacology characterises tirzepatide as an agonist at both the GIP receptor and the GLP-1 receptor. Receptor-signalling work has reported that its potency at the GIP receptor matches native GIP while its GLP-1 receptor activity is weaker and biased in its signalling profile — the “imbalanced agonist” description used by Willard and colleagues.
Structural studies using cryo-electron microscopy have mapped how tirzepatide occupies each receptor’s binding pocket, identifying the residues that allow one peptide to engage two different class-B receptors.
What kind of research has been published on Tirzepatide?
The discovery and pharmacological characterisation of LY3298176 was published in 2018 in Molecular Metabolism. Receptor-bias work followed in 2020, and structural determinants of the dual agonism were published in 2022. A large clinical development programme also exists in the literature; those results concern the registered medicine and its regulated use, not laboratory reference material.
The evidence cited here supports pathway and assay design. It is not evidence about any Lazarus Labs product.
What compounds is Tirzepatide studied alongside?
Tirzepatide sits in the incretin-receptor-agonist field and is routinely analysed alongside semaglutide (a GLP-1 receptor agonist) and retatrutide (a GIP/GLP-1/glucagon triple agonist). These groupings describe how the compounds appear in published research; they do not imply equivalence or any human-use indication.
How is Tirzepatide supplied, tested and handled?
Lazarus Labs supplies tirzepatide in 10MG and 30MG lyophilised research vials with third-party batch documentation and a published Certificate of Analysis (COA). Store cold, dry and protected from light in accordance with your laboratory protocol.
References
- Coskun T, Sloop KW, Loghin C, et al. Molecular Metabolism. 2018. PMID: 30473097.
- Willard FS, Douros JD, Gabe MB, et al. JCI Insight. 2020. PMID: 32730231.
- Sun B, Willard FS, Feng D, et al. Proceedings of the National Academy of Sciences. 2022. PMID: 35333651.
Primary literature, verified against PubMed. Citations are provided for scientific reference and do not imply a human-use indication.
Important
For research use only. Not for human or veterinary consumption. Tirzepatide is supplied solely as a laboratory reference material. Lazarus Labs makes no therapeutic, medical or performance claims, and nothing on this page is medical advice.